AFT Pharmaceuticals Limited

NZSE AFT.NZ

AFT Pharmaceuticals Limited Revenue Per Share for the year ending March 31, 2024: USD 1.11

AFT Pharmaceuticals Limited Revenue Per Share is USD 1.11 for the year ending March 31, 2024, a 19.88% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • AFT Pharmaceuticals Limited Revenue Per Share for the year ending March 31, 2023 was USD 0.93, a 8.09% change year over year.
  • AFT Pharmaceuticals Limited Revenue Per Share for the year ending March 31, 2022 was USD 0.86, a 12.67% change year over year.
  • AFT Pharmaceuticals Limited Revenue Per Share for the year ending March 31, 2021 was USD 0.76, a 18.36% change year over year.
  • AFT Pharmaceuticals Limited Revenue Per Share for the year ending March 31, 2020 was USD 0.64, a 8.61% change year over year.
Key data
Date Revenue Per Share Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA)
Market news
NZSE: AFT.NZ

AFT Pharmaceuticals Limited

CEO Dr. Hartley Atkinson Ph.D.
IPO Date Dec. 21, 2015
Location New Zealand
Headquarters 129 Hurstmere Road
Employees 110
Sector Health Care
Industries
Pharmaceuticals
Description

AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, and supplements, as well as other products. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.

StockViz Staff

January 15, 2025

Any question? Send us an email